RxDoctor Payments Data

Madhavi Gadiraju, MD

Internal Medicine · Midland, TXNPI 1932541406

Payments from drug & device makers

$3,857in general payments, 2019–2025

Across 241 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$743
  • AstraZeneca$554
  • Amgen$335
  • Novo Nordisk$272
  • GSK$267
  • Sanofi-aventis U.S. LLC$215
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,857100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,857 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$69,257
Medicare patients
173
Services billed
966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide52$70,315
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$64,026
OzempicSemaglutide38$63,845
JardianceEmpagliflozin44$63,195
MounjaroTirzepatide36$53,863
FarxigaDapagliflozin Propanediol31$46,372
JanuviaSitagliptin Phosphate32$45,973
EliquisApixaban23$30,060
LinzessLinaclotide13$15,165
VascepaIcosapent Ethyl17$11,021
SymbicortBudesonide/Formoterol Fumarate19$8,332
Varenicline Tartrate15$3,677
Albuterol Sulfate HfaAlbuterol Sulfate126$3,396
Levothyroxine Sodium303$2,351
Gabapentin125$2,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$743$124,17988 claims
GSKTrelegy Ellipta$267$64,02655 claims
Novo NordiskOzempic$272$63,84538 claims
Boehringer IngelheimJardiance$187$63,19544 claims
AstraZenecaFarxiga, Symbicort$554$54,70350 claims
MerckJanuvia$38$45,97332 claims
PfizerEliquis$213$30,06023 claims
AbbVieLinzess, Synthroid$129$17,05632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →